
usd aug pm et
summari compani focus discoveri develop therapeut treat metabol
disord cancer inflammatori diseas respiratori condit
price-to-earnings oper ep
concentr sale eylea expect
begin declin howev
formid drug asset dupix addit
strong financi posit think
risk valu medium
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
price target
base ep
ep vs beat
estim due
revenu regn antibodi licens
collabor agreement sanofi achiev
profit first time ahead
expect regn profit share relat
antibodi agreement million vs
loss million prior-year period
lift ep
ep
revenu increas billion net
product sale expand billion
sale recent launch dupix reach
million net product sale
grew year-over-year million
encourag hear announc today
phase trial dupix children
sever atop dermat met primari
secondari endpoint continu
bullish pipelin /kevin huang cfa
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc fulli integr biotechnolog
compani discov invent develop manufactur commerci medicin
treatment seriou diseas compani commerci medicin product candid
develop design help patient eye diseas allerg inflammatori diseas cancer
cardiovascular metabol diseas neuromuscular diseas infecti diseas rare diseas
regn core busi strategi maintain strong foundat basic scientif research
discovery-en technolog build foundat regn clinic develop
manufactur commerci capabl compani aim continu integr
multi-product biotechnolog compani provid patient medic profession import
option prevent treat human diseas
decemb market seven product eylea dupix praluent kevzara libtayo
arcalyst zaltrap eylea repres net product sale record
also reli partner collabor sell certain treatment certain geographi exampl
bayer record net product sale eylea outsid sanofi record global net product sale
dupix praluent kevzara zaltrap
competit landscap face substanti competit pharmaceut biotechnolog
chemic compani regn abil compet depend great extent fast develop safe
effect product candid complet clinic test approv process suppli
commerci quantiti product market competit among product candid approv
sale base efficaci safeti reliabl avail price patent posit factor
pipelin decemb product candid clinic develop
discov regn research laboratori
financi trend revenu grew billion reflect five-year compound annual
growth rate compound-annual-growth-rate adjust earn per share grew year-over-year reflect
five-year compound-annual-growth-rate typic maintain net cash posit gener billion
free cash flow defin oper cash flow less capit expenditur given compani
cash flow financi posit concern compani liquid abil
continu fund research develop effort
execut vice-president financ
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newly-approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
mega-d announc
acquisit celgen celg
acquisit botox manufactur
allergan industri debt level
still low risen last five year
cheap see sever matur
biopharmaceut firm made
mark blockbust drug look
off-set lost revenu expir patent
fail ventur promis late-stag
pipelin addit exampl see gilead
scienc like
acquir expect
interest off-set declin hcv
therapi sale expect engag
 activ make failur
biotechnolog compani low debt level
attract valuat rel
industri make favor
think growth biotechnolog
stock limit recent high
drug price come
heighten scrutini polit
apparatu last year despit
talk lower drug price
seen particularli sever measur taken
legisl regulatori bodi
lower drug price democrat took
hous repres
novemb mid-term elect appear
motiv address drug price
still think suffici impetu
effect signific chang near
futur anoth sourc price pressur
drug manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price pressur
like increas major pbm merg
major insur cvs-aet ci-esrx
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
sinc brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
maintain market domin longer
result expect biosimilar continu
advanc slowli next sever year
year-to-d june
biotechnolog index risen mere
compar rise valu
 composit index
declin
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra keep buy opinion share
inc lower price target base
ep ep vs beat
estim due higher-than-expect sanofi collabor revenu
regn antibodi licens collabor agreement sanofi
achiev profit first time ahead expect regn
profit share relat antibodi agreement million vs loss
million prior-year period lift ep
ep revenu increas
billion net product sale expand billion sale
recent launch dupix reach million net product sale
 grew year-over-year million encourag hear
announc today phase trial dupix children sever
atop dermat met primari secondari endpoint continu
bullish pipelin /kevin huang cfa
rais target
slightli peer forward ep estim faster
growth posit view compani pipelin ep vs
ahead estim rais ep estim
sale grew eylea treat advanc macular
degener sale global basi dupix
treat eczema sale record partner sanofi
quarter -- better anticip encourag pipelin progress
think second half year could receiv fda approv
cemiplimab advanc cutan squamou cell carcinoma fda action date
octob dupix asthma fda action date octob eylea wet
base dose interv fda action date august along
potenti regulatori file dupix adolesc atop dermat /jeffrey
pm et cfra keep buy opinion share
inc lower target base
ep ep vs lower
estim higher-than-expect expens cost
collabor contract manufactur expens yoy increas
 expens primarili attribut higher clinic trial
manufactur cost support wholli own program includ
new molecul light higher expect oper expens go
forward lower ep ep
sale key drug exceed expect across board
eylea sale increas billion libtayo second quarter
sale achiev million revenu dupix sale record
sanofi expand million continu favor view
regn robust pipelin recent launch product particularli
relat immuno-oncolog franchis /kevin huang cfa
inc lower target
above-p ep estim faster growth
ep vs ahead view yet note investor
concern sustain eylea franchis anticip
increas competit late believ expand eylea
market particularli diabet eye diseas sale rose strong sale
eylea elsewher dupix sale
forecast praluent sale remain modest see
sizeabl increas follow deal express script esrx
praluent exclus inhibitor nation
formulari juli esrx indic new net price low
end current estim although
earli determin volum gain deal view necessari
follow soft sale sinc juli approv /jeffrey loo cfa
pm et cfra keep buy opinion share
inc lift target
ep estim ep vs
higher estim one-tim increas sanofi collabor
revenu stronger-than-expect sale eylea rais ep
initi ep global eylea sale
increas billion includ net sale increas
year-over-year billion see underappreci upsid potenti
dupix potenti indic expans key regulatori
mileston dupix fda decis adolesc atop
dermat action date march ema decis
asthma adult adolesc potenti fda accept
supplement biolog licens applic chronic rhinosinus
nasal polyposi decemb product candid
lift target
ep estim ep vs
higher estim rais ep
ep global eylea sale increas
billion includ net sale increas
year-over-year billion revenu increas substanti
quarter due recognit portion million develop
mileston relat teva mitsubishi tanab pharma receiv fda
approv dupix octob patient moderate-to-sever
asthma launch sale expand indic launch libtayo
cemiplimab approv septemb treatment cutan
squamou cell carcinoma cscc also way continu see
underappreci strength portfolio commerci clinic
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
